dideoxycystine

• 分子结构分类: 有机化合物 - 有机硫化合物 - 有机二硫化物
• 英文名称: dideoxycystine
• 英文别名: (2R)-2-amino-3-[[(2R)-2-amino-3-oxopropyl]disulfanyl]propanal
• 化学式: C₆H₁₂N₂O₂S₂
• 分子量: 208.305
• InChiKey: ZLGRRCFMBVNIOG-PHDIDXHHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  137
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  dideoxycystine 在 二茂铁 作用下， 以 四氢呋喃 为溶剂， 以17%的产率得到
  参考文献：
  名称：

  {Co(NO)2}10 复合物促进半胱氨酸的 S-亚硝化

  摘要：

  S-亚硝基硫醇 (SNO) 作为活细胞内 NO 的内源性载体和供体，释放亚硝鎓离子 (NO + )、NO 或其他亚硝基衍生物。在这项研究中，我们提出了一种受生物启发的{Co(NO) 2 } 10复合物1，它实现了对Cys残基的S-亚硝化。在1中引入二茂铁基团可以利用 Cys 残基的氧化还原能力对亚硝化反应进行微调。合成并表征了复合物1 ，证明了其 NO 翻译反应活性。此外，经 UV-Vis、IR 和 XAS 光谱证实，复合物1成功地将 Cys 转化为S-亚硝基半胱氨酸 (Cys-SNO)。这项研究提出了一种有前景的半胱氨酸残基S 亚硝化方法，可进一步探索含半胱氨酸肽的修饰。

  DOI：

  10.1039/d3cc02784h

文献信息

• USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY
  申请人：IPSEN PHARMA S.A.S.

  公开号：EP2979703B1

  公开（公告）日：2018-07-18
• Zalcitabine (Ddc) Boosted Lamivudine (3Tc) Compositions for Antiretroviral Therapy
  申请人：Toma Emil

  公开号：US20080214590A1

  公开（公告）日：2008-09-04

  Boosted cytidine analogue reverse transcriptase inhibitor antiretroviral compound is a new therapeutic anti HIV option, in combination with another drug such as a NRTI or a protease inhibitor. It's heightened and sustained antiretroviral potency is due to the increased intracellular level of 3TC triphosphate, the active form of 3TC. This effect is obtained by combining 3TC, in usual doses, with a reduced dose of ddC, in the same pharmaceutical formulation. The product could be administered twice or even once daily, which is convenient, and does not increase the pill burden for the patient. The reduced ddC dosage prevents the occurrence of ddC related side effects. Other cytidine derivatives (racemic or negative enantiomers) could have the same effects as ddC and could probably be combined with 3TC, and have the same effect. On the other hand, low dose ddC may also increase the intracellular levels of other cytidine derivatives as it does for 3TC. Boosted cytidine analogue reverse transcriptase inhibitor antiretroviral compound could also be formulated in combination with another drug such as another NRTI (e.g. abacavir) or any protease inhibitor in the same capsule or tablet. This approach offers a dual anti-HIV therapy that is as efficacious as the routine triple therapy. In this way the HIV treatment cost could be significantly reduced which is imperative for resource-poor settings. This new formulation is convenient and well tolerated with no additional toxicity than that of the combining drug (NRTI or protease inhibitor) and 3TC. Moreover, this will enable a larger number of patients to benefit from the already known 3TC effects. It will also increase the 3TC effects in those organs or HIV sanctuaries with usually reduced 3TC concentrations or activity. It could be indicated in both the initial as well as in salvage HIV therapy. It could also be used for therapy optimization or simplification. Moreover, in combination with another NRTI such as abacavir, or even alone, it could be beneficial for reducing the HIV harm in resource-poor settings.
• MELANOCORTIN RECEPTOR LIGANDS MODIFIED WITH HYDANTOIN
  申请人：Ipsen Pharma S.A.S.

  公开号：US20180118784A1

  公开（公告）日：2018-05-03

  The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
• METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS
  申请人：CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN

  公开号：US20210169970A1

  公开（公告）日：2021-06-10

  The disclosure is related to a method of treating a disorder, such as Prader Willi Syndrome (PWS), obesity or hyperphagia, in a subject using a melanocortin-4 receptor (MC4R) agonist. Also described is method of treating a subject having a deficiency in the pro-opiomelanocortin (POMC)-MC4R pathway, such as a POMC-null or a PC SK-null subject, using a MC4R agonist.
• US4971977A
  申请人：——

  公开号：US4971977A

  公开（公告）日：1990-11-20